News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,028 Results
Type
Article (41804)
Company Profile (329)
Press Release (662895)
Section
Business (210123)
Career Advice (2074)
Deals (36571)
Drug Delivery (96)
Drug Development (82795)
Employer Resources (171)
FDA (16476)
Job Trends (15356)
News (355380)
Policy (33818)
Tag
Academia (2574)
Alliances (51076)
Alzheimer's disease (1246)
Approvals (16407)
Artificial intelligence (140)
Bankruptcy (362)
Best Places to Work (11668)
Biotechnology (214)
Breast cancer (122)
Cancer (1102)
Cardiovascular disease (102)
Career advice (1737)
Cell therapy (236)
Clinical research (65770)
Collaboration (392)
Compensation (199)
COVID-19 (2601)
C-suite (96)
Data (1128)
Diabetes (154)
Diagnostics (6223)
Earnings (86501)
Employer resources (149)
Events (112304)
Executive appointments (316)
FDA (17017)
Funding (352)
Gene therapy (186)
GLP-1 (609)
Government (4444)
Healthcare (18850)
Infectious disease (2685)
Inflammatory bowel disease (110)
Interviews (319)
IPO (16573)
Job creations (4050)
Job search strategy (1487)
Layoffs (433)
Legal (8318)
Lung cancer (172)
Manufacturing (185)
Medical device (13259)
Medtech (13264)
Mergers & acquisitions (20062)
Metabolic disorders (417)
Neuroscience (1530)
NextGen Class of 2024 (6624)
Non-profit (4512)
Northern California (1482)
Obesity (239)
Opinion (203)
Patents (104)
People (58221)
Pharmaceutical (92)
Phase I (20340)
Phase II (28945)
Phase III (21711)
Pipeline (456)
Postmarket research (2643)
Preclinical (8673)
Radiopharmaceuticals (240)
Rare diseases (227)
Real estate (6240)
Regulatory (22360)
Research institute (2357)
Resumes & cover letters (358)
Southern California (1304)
Startups (3711)
United States (13567)
Vaccines (567)
Weight loss (182)
Date
Today (142)
Last 7 days (818)
Last 30 days (3794)
Last 365 days (36152)
2024 (33129)
2023 (40628)
2022 (51797)
2021 (56331)
2020 (54795)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (199)
Asia (39984)
Australia (6393)
California (3332)
Canada (1290)
China (252)
Colorado (145)
Connecticut (154)
Europe (85135)
Florida (458)
Georgia (116)
Illinois (347)
Indiana (204)
Kansas (96)
Maryland (580)
Massachusetts (2636)
Michigan (158)
Minnesota (272)
New Jersey (965)
New York (955)
North Carolina (716)
Northern California (1482)
Ohio (138)
Pennsylvania (846)
South America (1157)
Southern California (1304)
Texas (468)
Washington State (364)
705,028 Results for "ampio pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Ampio Pharmaceuticals, Inc. announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern.
April 3, 2024
·
1 min read
Ampio Provides Update on Results from Pre-IND Enabling Studies
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”) today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio’s only product development opportunity.
February 14, 2024
·
3 min read
Policy
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Pharmaceuticals, Inc. announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended.
March 25, 2024
·
4 min read
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company) today announced that it has selected Ascendia Pharmaceuticals, Inc. (“Ascendia”) to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.
October 5, 2023
·
5 min read
BioMidwest
Ampio Pharmaceuticals Announces Reverse Stock Split
Ampio Pharmaceuticals, Inc. announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company’s common stock.
August 31, 2023
·
4 min read
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, October 5, 2023 at 3:25 pm ET.
September 26, 2023
·
3 min read
BioMidwest
Ampio Pharmaceuticals Issues Letter to Stockholders - April 18, 2023
Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
April 18, 2023
·
7 min read
Policy
Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).
November 29, 2022
·
1 min read
BioMidwest
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock
Ampio Pharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023.
May 26, 2023
·
5 min read
Business
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS - January 17, 2023
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
January 17, 2023
·
5 min read
1 of 70,503
Next